Maria Symiakaki/ LinkedIn
May 29, 2026, 09:50
Maria Symiakaki: Advancing Cardiovascular Prevention at the 2026 Congress of the European Atherosclerosis Society
Maria Symiakaki, Co-Founder and Public Affairs Business Development Director at Solutions for Rare Diseases (SfRD), shared a post on LinkedIn:
“Happy to attend the 2026 Congress of the European Atherosclerosis Society.
It was an excellent opportunity for global leaders in lipidology and preventive cardiology to reconnect, exchange ideas, and explore the future of cardiovascular prevention and lipid management.
Key highlights included the release of the new EAS consensus on pediatric familial hypercholesterolemia (FH), as well as advances in global lipid clinic networks.
Importantly, patient voices continue to play a central role in shaping cardiovascular health policy and care pathways across Europe.”
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment